Autoimmune neuropathies and treatment with intravenous immunoglobulins. Issue 5 (September 2005)

• Record Type: Journal Article
• Authors: Simovic, Drasko
• Is Part Of: Therapy. Volume 2:Issue 5(2005)
• Page Start: 797
• Page End: 805
• Publication Date: 2005-09
• Subjects: chronic inflammatory demyelinating polyneuropathy Guillain––Barréé syndrome -- intravenous immunoglobulins -- monoclonal gammopathy of undetermined significance -- multifocal motor neuropathy -- neuropathy; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/14750708.2.5.797
• Languages: English
• ISSNs: 1475-0708

Abstract

Intravenous immunoglobulins are an effective treatment for a variety of immune-mediated neuropathies. The benefits have been recognized from the controlled studies for Guillain––Barréé syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. In monoclonal gammopathy of undetermined significance and neuropathy, the effectiveness is variable. Tolerability of intravenous immunoglobulins is very good and adverse reactions are usually minor. Further controlled trials are needed to assess the efficacy of secondary intravenous immunoglobulin infusion in nonresponders in Guillain––Barréé syndrome, maintenance intravenous immunoglobulin dose and frequency in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, efficacy of intravenous immunoglobulins in diabetes-associated chronic inflammatory demyelinating polyneuropathy and the benefits of combination therapy with other immunomodulating medications.